Michael T. Pulley M.D., Ph.D. Professor Department: Department of Neurology Business Phone: (904) 244-9922 Business Email: michael.pulley@jax.ufl.edu Appointments and Locations Board Certifications NeurologyClinical Neurophysiology Show More Clinical Profile Specialties Clinical NeurophysiologyMultiple SclerosisNeurologyNeuromuscular Medicine Interests Clinical Special Interests: Neuromuscular diseases and EMG Show More Publications 2025A 40-week phase 2B randomized, multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosis.Muscle & nerve.71(1):63-72[DOI] 10.1002/mus.28287.[PMID] 39511965.1 citations·PubMed·Publisher's Site2025Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.The Lancet. Neurology.24(2):117-127[DOI] 10.1016/S1474-4422(24)00514-3.[PMID] 39862880.5 citations·PubMed·Publisher's Site2023Primary lateral sclerosis natural history study - planning, designing, and early enrollment.Amyotrophic lateral sclerosis & frontotemporal degeneration.24(5-6):394-404[DOI] 10.1080/21678421.2022.2161912.[PMID] 36576200.3 citations·PubMed·Publisher's Site2023Randomized Double-Blind Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis.Neurology.100(7):e671-e682[DOI] 10.1212/WNL.0000000000201501.[PMID] 36270895.12 citations·PubMed·Publisher's Site2022Patient preference for virtual versus in-person visits in neuromuscular clinical practice.Muscle & nerve.66(2):142-147[DOI] 10.1002/mus.27641.[PMID] 35596667.7 citations·PubMed·Publisher's Site2021A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS.Amyotrophic lateral sclerosis & frontotemporal degeneration.22(3-4):287-299[DOI] 10.1080/21678421.2020.1822410.[PMID] 32969758.47 citations·PubMed·Publisher's Site2021Individualizing Therapy in CIDP: A Mini-Review Comparing the Pharmacokinetics of Ig With SCIg and IVIg.Frontiers in neurology.12():638816-[DOI] 10.3389/fneur.2021.638816.[PMID] 33763019.9 citations·PubMed·Publisher's Site2021Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized Trial.JAMA neurology.78(1):68-76[DOI] 10.1001/jamaneurol.2020.2590.[PMID] 32809014.28 citations·PubMed·Publisher's Site2020Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.JAMA neurology.77(5):582-592[DOI] 10.1001/jamaneurol.2019.5125.[PMID] 32065623.122 citations·PubMed·Publisher's Site2020Minimal manifestation status and prednisone withdrawal in the MGTX trial.Neurology.95(6):e755-e766[DOI] 10.1212/WNL.0000000000010031.[PMID] 32611638.15 citations·PubMed·Publisher's Site2020Optimizing telemedicine to facilitate amyotrophic lateral sclerosis clinical trials.Muscle & nerve.62(3):321-326[DOI] 10.1002/mus.26921.[PMID] 32415876.22 citations·PubMed·Publisher's Site2019Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.The Lancet. Neurology.18(3):259-268[DOI] 10.1016/S1474-4422(18)30392-2.[PMID] 30692052.131 citations·PubMed·Publisher's Site2019Multidisciplinary amyotrophic lateral sclerosis telemedicine care: The store and forward method.Muscle & nerve.59(1):34-39[DOI] 10.1002/mus.26170.[PMID] 29802746.23 citations·PubMed·Publisher's Site2019Statin-associated muscle symptoms: Does the benefit outweigh the risk factor?Muscle & nerve.59(5):525-527[DOI] 10.1002/mus.26470.[PMID] 30882912.1 citations·PubMed·Publisher's Site2019Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis.Muscle & nerve.59(4):404-410[DOI] 10.1002/mus.26404.[PMID] 30575980.52 citations·PubMed·Publisher's Site2017Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.Neurology.89(10):1069-1077[DOI] 10.1212/WNL.0000000000004341.[PMID] 28801338.157 citations·PubMed·Publisher's Site2016A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.Neurology.87(1):57-64[DOI] 10.1212/WNL.0000000000002795.[PMID] 27306628.77 citations·PubMed·Publisher's Site2011Randomized, Double-Blind, Placebo-Controlled, Crossover, Multicenter, Phase Ii Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis (Gmg).44():689-690[DOI] .[PMID] .PubMed·Publisher's Site2007Hemorrhagic upper extremity complications from tissue plasminogen activator.Journal of surgical orthopaedic advances.16(1):27-30[DOI] .[PMID] 17371644.3 citations·PubMed·Publisher's Site1992Immunocytochemical expression of the endothelial barrier antigen (EBA) during brain angiogenesis.Brain research. Developmental brain research.66(1):47-54[DOI] .[PMID] 1376220.77 citations·PubMed·Publisher's Site Show More Office Information Academic Office 9th Floor, Tower I580 West 8th Street, T17Jacksonville, FL 32209(904) 244-9922 michael.pulley@jax.ufl.edu Administrative Manager Cecily Pate(904) 244-9922Cecily.Pate@jax.ufl.edu Show More Clinical Research An Outpatient Physical Therapy and Golf Program Designed for Individuals with Movement Disorders A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (20202174) Long-Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies (20193186) Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (20203748) A phase 3, multi-center, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of reldesemtiv in patients with amyotrophic lateral sclerosis (als) (20211633) Education Medical Degree1993 · University of Maryland School of Medicine, Baltimore, MD, USANeurology Residency1997 · Duke University Hospital, Durham, NC, USAClinical Neurophysiology Fellowship1998 · The Johns Hopkins University School of Medicine, Baltimore, MD, USA Show More News July 1, 2022 21 UF COMJ faculty members receive promotions for 2022-23 June 21, 2019 UF COMJ faculty members recognized for service milestones March 10, 2017 Compassion and research are the foundation for UF Health’s Comprehensive MS Program March 4, 2014 Telemedicine Pilot Program makes care more accessible for ALS patients February 27, 2012 More than 60 residents, faculty honored in Celebration of Excellence in Medical Education Media Coverage May 5, 2020 May is ALS Awareness Month News4Jax (WJXT) February 4, 2019 ALS association names UF Health 'treatment center of excellence' News4Jax (WJXT) January 30, 2019 Treatment Center of Excellence for ALS News4Jax (WJXT) Multimedia September 4, 2012 Amyotrophic Lateral Sclerosis: Anne Johnson's Story